LTRN Lantern Pharma Quarterly EPS earnings growth

Official company branding of Lantern (LTRN)

Lantern Pharma Inc. (LTRN) monetizes AI technologies by receiving payments for the development of personalized oncology drugs. The firm's strategy is based on expansion within the targeted therapy segment and the acceleration of LP-300 trials. Low geopolitical risks in the US ensure the stability of research. The current quarterly EPS growth value demonstrates profit dynamics, where -42.10 shows the value of this parameter on the chart.

Lantern Pharma (LTRN) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

LTRN (Lantern Pharma): analytical breakdowns and indicator data

- share price and expert price forecast:
Summary company analysis:Lantern Pharma Inc, LTRN
Flagship merchandise of lanternpharma.com

For Lantern Pharma Inc. (LTRN), which utilizes machine learning to develop cancer therapies, the quarterly change in earnings per share reflects the efficiency of monetizing its intellectual databases. This indicator is calculated as the percentage deviation of the current EPS from the value of the same period last year, measuring the business's ability to generate real returns on capital and hedge against inflationary risks.